Characteristic Bioactive Libraries

A unique collection of 5100 human metabolites for high-throughput, high-content screening.

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 653 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 250 compounds targeting chromatin remodeling pathway for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1001 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening；

210 macrocyclic compounds of known activity for high-throughput, high-content screening;

A unique collection of 660 CNS-Penetrant compounds for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 898 compounds with unique structures targeting transcription factor;

A unique collection of 334 nucleoside and nucleotide analogues, can be used for research and development of anti-viral, anti-tumor, anti-fungal, and anti-depressive drugs;

A unique collection of 218 mouse metabolites, which can be used for HTS and HCS;

80 species of cyclic peptide molecules for high-throughput and high-content screening;

The cysteine covalent library contains 150 compounds.

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening；

A unique collection of 3059 metabolic pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 1593 stem cell differentiation signaling targeted compounds for high throughput and high content screening;

791 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A unique collection of 385 bioactive lipids related compounds for high throughput screening (HTS) and high content screening (HCS), including Agonists & Antagonists, Endocannabinoids, Farnesyl geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsa

A unique collection of 131 cardiotoxicity inducing compounds for toxicological study;

460 food additives;

A unique collection of 469 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 485 PPI-related compounds for drug screening;

A unique collection of 924 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 2400 covalent Inhibitors and other molecules with common warheads like chloroacetyl，2-Chloropropionyl，Acryloyl，sulfonyl fluoride, alkyne，acrylamide, ketocarbonyl，disulfide bond, etc.

A unique collection of 3160 of orally active compounds for high-throughput screening and high-content screening.

A unique collection of 144 procoagulation and anticoagulation related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 317 osteogenesis related compounds for high throughput and high content screening;

A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;

A unique collection of 972 pediatric drugs for high-throughput screening and high-content screening.

555 glycolysis-related active compounds for high-throughput and high-content screening.

A unique collection of 941 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

A unique collection of 149 neuroregeneration related compounds for high throughput and high content screening;

A unique collection of 2240 reprogramming signaling pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 262 toxic substances for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2684 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS);

A unique collection of 197 drug isomers metabolites for high throughput screening (HTS) and high content screening (HCS);

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of 1314 small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.

A unique collection of 105 beta-lactam compounds, can be used in HTS and HCS;

1196 glycometabolism-related comounds, can be used for HTS and HCT;

A Collection of 182 inactive ingredients from FDA-approved drugs.

A unique collection of 270 pesticide-related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4080 compounds for high-throughput screening and high-content screening,

A unique collection of 692 compounds with antibiotic activity for new antibacterial drug screening;

A unique collection of 800 of cosmetic ingredient compounds.

1264 small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

TargetMol created the L4020 NO-PAINS Compound Library that applied the PAINS filter, remaining 9384 small molecules that are suitable for new drug development, signaling pathway research, drug repurposing and other research.